Form 4: Veracyte CFO Sells 7,000 Shares Under 10b5-1 Plan
Insider Transaction Report
Veracyte's Chief Financial Officer, Rebecca Chambers, sold 7,000 shares of common stock for $41 per share on November 5, 2025, as part of a pre-arranged 10b5-1 plan.
Summary
- Rebecca Chambers, Chief Financial Officer of Veracyte, Inc. (VCYT), reported a transaction involving the company's common stock.
- On November 5, 2025, Chambers disposed of 7,000 shares of Veracyte Common Stock.
- The shares were sold at a price of $41 per share.
- This transaction was executed pursuant to a Rule 10b5-1 plan, which was adopted by the reporting person on August 13, 2024.
- Following this reported transaction, Chambers beneficially owns 126,158 shares of Common Stock directly.
Sentiment
Score: 5
Explanation: Neutral. This is a routine insider transaction under a pre-arranged 10b5-1 plan, which typically indicates a planned diversification or liquidity event rather than a signal about the company's immediate prospects.
Future Outlook
NA
Industry Context
This Form 4 filing details a routine insider transaction, which is common across all industries as executives manage personal finances and portfolio diversification. It does not provide broader industry context or trends.
Stakeholder Impact
- Shareholders: May observe an insider sale, but the pre-arranged 10b5-1 plan mitigates concerns about negative sentiment regarding the company's future performance, as these sales are not typically based on new, non-public information.
Key Dates
| Date | Description |
|---|---|
| August 13, 2024 | Date Rule 10b5-1 plan was adopted by Rebecca Chambers. |
| November 5, 2025 | Date of transaction where 7,000 shares were disposed of. |
| November 7, 2025 | Date Form 4 was signed and filed. |
Recommendation
holdThe reported transaction is a routine insider sale by the Chief Financial Officer under a pre-arranged Rule 10b5-1 plan. Such plans are typically established for personal financial planning, diversification, or liquidity purposes and do not necessarily reflect a change in the insider's view of the company's future prospects. Without additional information on company performance or strategic shifts, this event alone does not warrant a change from a 'hold' recommendation.
Keywords
Veracyte, VCYT, Rebecca Chambers, Insider Trading, Form 4, Stock Sale, 10b5-1 Plan, Chief Financial Officer, Common Stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.